EPA:ABNX - Euronext Paris - Matif - FR0012616852 - Common Stock - Currency: EUR
EPA:ABNX (6/18/2025, 1:29:08 PM)
1.238
-0.01 (-0.64%)
The current stock price of ABNX.PA is 1.238 EUR. In the past month the price decreased by -0.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1ABBV.MI | ABBVIE INC | 18.69 | 293.65B | ||
4AB.DE | ABBVIE INC | 18.09 | 283.68B | ||
AMG.DE | AMGEN INC | 14.23 | 137.38B | ||
GIS.DE | GILEAD SCIENCES INC | 14.11 | 117.44B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 99.51B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 11.98 | 49.56B | ||
ARGX.BR | ARGENX SE | 102.34 | 28.87B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.80B | ||
IDP.DE | BIOGEN INC | 8.15 | 16.35B | ||
1EXEL.MI | EXELIXIS INC | 18.93 | 9.81B | ||
1MRNA.MI | MODERNA INC | N/A | 8.71B | ||
0QF.DE | MODERNA INC | N/A | 8.67B |
ABIONYX Pharma SA engages in the in discovery and development of novel therapies for patients without existing or effective treatments. The company is headquartered in Balma, Occitanie and currently employs 51 full-time employees. The company went IPO on 2015-03-30. The Company’s product portfolio comprises Cerenis HDL and HDL enhancers that is designed to regress atherosclerotic plaque among patients at high risk of cardiovascular events, among others. Additionally, the Company has a portfolio of clinical and preclinical HDL programs. The firm is present in Labege in Midi-Pyrenees in France and in Ann Arbor in Michigan in the United States. In addition, it also operates through LYPRO Biosciences Inc.
ABIONYX PHARMA SA
Bat. D 33-43 Avenue Georges Pompidou
Balma OCCITANIE FR
Employees: 51
Phone: 33562249706
The current stock price of ABNX.PA is 1.238 EUR. The price decreased by -0.64% in the last trading session.
The exchange symbol of ABIONYX PHARMA SA is ABNX and it is listed on the Euronext Paris - Matif exchange.
ABNX.PA stock is listed on the Euronext Paris - Matif exchange.
8 analysts have analysed ABNX.PA and the average price target is 10.97 EUR. This implies a price increase of 785.7% is expected in the next year compared to the current price of 1.238. Check the ABIONYX PHARMA SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ABIONYX PHARMA SA (ABNX.PA) has a market capitalization of 43.24M EUR. This makes ABNX.PA a Nano Cap stock.
ABIONYX PHARMA SA (ABNX.PA) currently has 51 employees.
ABIONYX PHARMA SA (ABNX.PA) has a support level at 1.24 and a resistance level at 1.25. Check the full technical report for a detailed analysis of ABNX.PA support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ABNX.PA does not pay a dividend.
ABIONYX PHARMA SA (ABNX.PA) will report earnings on 2025-09-25.
ABIONYX PHARMA SA (ABNX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.13).
ChartMill assigns a fundamental rating of 3 / 10 to ABNX.PA. While ABNX.PA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months ABNX.PA reported a non-GAAP Earnings per Share(EPS) of -0.13. The EPS decreased by -7.36% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -32.35% | ||
ROE | -58.3% | ||
Debt/Equity | 0.25 |
ChartMill assigns a Buy % Consensus number of 85% to ABNX.PA. The Buy consensus is the average rating of analysts ratings from 8 analysts.